1. Home
  2. ALEC

as 05-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Founded: 2013 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 524.3M IPO Year: 2019
Target Price: $14.17 AVG Volume (30 days): 602.0K
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.38 EPS Growth: N/A
52 Week Low/High: $3.66 - $9.06 Next Earning Date: 05-08-2024
Revenue: $96,406,000 Revenue Growth: -23.30%
Revenue Growth (this year): -32.62% Revenue Growth (next year): 58.10%

ALEC Daily Stock ML Predictions

Stock Insider Trading Activity of Alector Inc. (ALEC)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Romano Gary ALEC Chief Medical Officer Mar 4 '24 Sell $6.92 6,001 $41,553.92 196,313 SEC Form 4
GRASSO MARC ALEC Chief Financial Officer Mar 4 '24 Sell $6.92 5,716 $39,561.58 144,957 SEC Form 4
GRASSO MARC ALEC Chief Financial Officer Dec 4 '23 Sell $5.56 4,574 $25,431.44 150,673 SEC Form 4
Kenkare-Mitra Sara ALEC President and Head of R&D Dec 4 '23 Sell $5.56 12,519 $69,605.64 329,016 SEC Form 4
Rosenthal Arnon ALEC Chief Executive Officer Dec 4 '23 Sell $5.56 23,831 $132,500.36 2,019,217 SEC Form 4

Share on Social Networks: